Jörger Philippa, Nigg Carina, Žarković Maša, Sommer Grit, Kompis Martin, Michel Gisela, Ansari Marc, Waespe Nicolas, Kuehni Claudia E
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Patient Educ Couns. 2025 Jul;136:108764. doi: 10.1016/j.pec.2025.108764. Epub 2025 Mar 27.
The International Guideline Harmonization Group recommends childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the risk of hearing loss. We assessed awareness among adult CCS.
We identified adults diagnosed with cancer < 20 years who received ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and invited them to the HEAR-study. Participants completed a questionnaire and underwent pure-tone audiometry. Cancer and treatment data were obtained from the ChCR. We used logistic regression to explore factors influencing awareness.
Of 424 invited, 105 CCS participated (25 %). Fifty-seven percent did not remember receiving information on hearing loss prior to the study. CCS who remembered being informed were more likely diagnosed after 1995 (OR: 4.5, 95 % CI: 1.3-15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus cranial radiotherapy only. 44 % of participants presented clinically relevant hearing loss.
Over half of CCS exposed to ototoxic treatments were unaware of their risk of hearing loss.
Educating CCS about potential late effects of ototoxic treatments is important to allow early diagnosis and treatment, especially for those who had cancer longer ago and those exposed to cranial radiation.
国际指南协调小组建议，接受耳毒性治疗的儿童癌症幸存者（CCS）应了解听力损失风险。我们评估了成年CCS对此风险的知晓情况。
我们通过瑞士儿童癌症登记处（ChCR）确定了在20岁之前被诊断为癌症且接受过耳毒性治疗的成年人，并邀请他们参加听力研究（HEAR-study）。参与者完成了一份问卷并接受了纯音听力测定。癌症和治疗数据来自ChCR。我们使用逻辑回归来探索影响知晓情况的因素。
在424名被邀请者中，105名CCS参与了研究（25%）。57%的人在研究前不记得曾收到过关于听力损失的信息。记得曾被告知的CCS更有可能在1995年之后被诊断出癌症（比值比：4.5，95%置信区间：1.3 - 15.4），报告有听力问题（10.9，2.6 - 45.1）和其他晚期效应（4.1，1.3 - 13.2），并且仅接受铂类化疗（10.8，2.2 - 53.2）而非仅接受颅脑放疗。44%的参与者存在临床相关的听力损失。
超过一半接受耳毒性治疗的CCS未意识到自己有听力损失风险。
对CCS进行耳毒性治疗潜在晚期效应的教育，对于实现早期诊断和治疗非常重要，特别是对于那些患癌时间较早以及接受过颅脑放疗的患者。
